Result of AGM

RNS Number : 7198B

ValiRx PLC

20 June 2016

 

ValiRx Plc

("ValiRx" or "the Company")

RESULT OF ANNUAL GENERAL MEETING

London, UK, 20^th June 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that at its Annual General Meeting ("AGM") held earlier today, Resolutions 1 to 5 were passed.  Resolution 6, whilst supported by the majority of Shareholders, did not receive the necessary level of support to be passed at this time.  A further announcement will follow in due course.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Mark Treharne, Corporate Development Manager	Tel: [phone] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray
Northland Capital Partners Limited (Joint Broker)	Tel: [phone]
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking)
Beaufort Securities Limited (Joint Broker)	Tel: [phone]
Jon Belliss

 

END

 

 

RAGSEEFDSFMSEEM